Philip Goelet

Philip has extensive experience as a scientist, entrepreneur, and investor. His scientific career started at the Laboratory of Molecular Biology (LMB, Cambridge UK) under the supervision of Jon Karn in the laboratory of Sydney Brenner, where he sequenced tobacco mosaic virus as part of his Ph.D. at the University of Cambridge. He then pursued postdoctoral research in neuroscience at Columbia University with Nobel Laureate Eric Kandel. Prior to co-founding Acidophil, Philip co-founded and managed Molecular Tool (Baltimore, MD: pioneering single nucleotide polymorphism analysis, acquired by Orchid Biosciences) and RiboTargets (Cambridge UK: therapeutics based upon targeting RNA, merged with Vernalis). In parallel to co-founding Acidophil with Sydney Brenner, Philip co-founded Red Abbey Venture Partners, a health care private equity fund with Frank Bonsal and Matt Zuga.